June 23, 2025– Hoyotek Biomedical Co., Ltd. and Wantai BioPharm Co., Ltd. announced a strategic collaboration to co-develop precision diagnostic solutions for neurodegenerative disorders. The partnership will integrate Hoyotek's expertise in neurological biomarkers with Wantai's commercialization capabilities to create end-to-end solutions spanning early detection, diagnosis, and monitoring.
Synergizing Strengths in Brain Health Innovation
The signing ceremony brought together leadership teams from both organizations. Wantai was represented by Marketing GM Jing Weihong, Marketing Director Zhang Yu, and key commercial leaders, while Hoyotek's delegation included GM Wu Bo and senior executives.
Jing Weihong emphasized: "This alliance combines our complementary strengths to accelerate breakthroughs in Alzheimer's diagnostics. Together, we can deliver more reliable tools for clinical decision-making throughout the disease management continuum."
Wu Bo noted: "Aligning with national dementia initiatives, we're committed to developing accessible solutions that address our aging population's needs. Wantai's global platform will amplify this mission. At Hoyotek, we have been, are now, and will always remain committed to Alzheimer's detection."
Addressing a Growing Public Health Challenge
With China's 60+ population reaching 310 million (22% of total) and nearly 10 million Alzheimer's cases, the collaboration responds to urgent demands highlighted in China's 2024-2030 dementia action plan. The partners aim to improve early detection rates and secure the golden window for non-pharmacological therapies through innovative diagnostics.
Technology Leaders Joining Forces
Hoyotek brings proprietary chemiluminescence technology and specialized neurological test kits already serving 100+ institutions globally. Wantai contributes its vaccine and diagnostic commercialization expertise, including international distribution networks.
Under this strategic partnership, Wantai Biopharm will fully leverage its integrated end-to-end industrial chain capabilities, while Hoyotek will contribute its cutting-edge core technologies in neurological disease detection. Together, we will provide healthcare institutions and patients with more accurate and convenient testing services to meet the growing demands for advanced health management solutions.